1. Horn-Ross PL. Melanoma in the Greater San Francisco Bay Area 1988-2000. Northern California Cancer Center (serial online) (citado marzo 2003). Disponible en: URL: http://www.nccc.org/pdf/poc/ melanoma_factsheet_88-2000.pdf.
2. Saenz S, Conejo-Mir J, Cayuela A. Melanoma epidemiology in Spain. Actas Dermosifiliogr. 2005; 96(7): 411-8.
3. Weinstock MA. Progress and prospects on melanoma: the way forward for early detection and reduced mortality. Clin Cancer Res. 2006;12(7 Pt 2): 2297s-2300s.
4. De Braud F, Khayat D, Kroon BB, Valdagni R, Bruzzi P, Cascinelli N. Malignant melanoma. Crit Rev Oncol Hematol. 2003; 47(1): 35-63.
5. Lesinski GB, Kondadasula SV, Crespin T, Shen L, Kendra K, Walker M, Carson WE 3rd. Multiparametric flow cytometric analysis of inter-patient variation in STAT1 phosphorylation following interferon Alfa immunotherapy. J Natl Cancer Inst. 2004; 96(17): 1331-42.
6. Caraglia M, Marra M, Pelaia G, Maselli R, Caputi M, Marsico SA, Abbruzzese A. Alpha-interferon and its effects on signal transduction pathways. J Cell Physiol. 2005; 202(2): 323-35.
7. Maellaro E, Pacenti L, Del Bello B, Valentini MA, Mangiavacchi P, De Felice C, Rubegni P, Luzi P, Miracco C. Different effects of interferon-alpha on melanoma cell lines: a study on telomerase reverse transcriptase, telomerase activity and apoptosis. Br J Dermatol. 2003; 148(6): 1115-24.
8. Raffaella R, Gioia D, De Andrea M, Cappello P, Giovarelli M, Marconi P, Manservigi R, Gariglio M, Landolfo S. The interferon-inducible IFI16 gene inhibits tube morphogenesis and proliferation of primary, but not HPV16 E6/E7-immortalized human endothelial cells. Exp Cell Res. 2004; 293(2): 331-45.
9. Ala-aho R, Johansson N, Grenman R, Fusenig NE, Lopez-Otin C, Kahari VM. Inhibition of collagenase-3 (MMP-13) expression in transformed human keratinocytes by interferon-gamma is associated with activation of extracellular signal-regulated kinase-1,2 and STAT1. Oncogene. 2000; 19(2): 248-57.
10. Abuzahra F, Heise R, Joussen S, Dreuw A, Merk H, Zwadlo-Klarwasser G, Baron JM. Adjuvant interferon alfa treatment for patients with malignant melanoma stimulates transporter proteins associated with antigen processing and proteasome activator 28. Lancet Oncol. 2004; 5(4): 250.
11. Menon Y, Cucurull E, Reisin E, Espinoza LR. Interferon-alpha-associated sarcoidosis responsive to infliximab therapy. Am J Med Sci. 2004; 328(3): 173-5.
12. Yang H, Dithmar S, Grossniklaus HE. Interferon alpha 2b decreases hepatic micrometastasis in a murine model of ocular melanoma by activation of intrinsic hepatic natural killer cells. Invest Ophthalmol Vis Sci. 2004b; 45(7): 2056-64.
13. Pawlik TM, Sondak VK. Malignant melanoma. Current state of primary and adjuvant treatment. Crit Rev Oncol Hematol. 2003; 45: 245-64.
14. Panthong A, Supraditaporn W, Kanjanapothi D, Taesotikul T, Reutrakul V. Analgesic, anti-inflammatory and venotonic effects of Cissus quadrangularis Linn. J Ethnopharmacol. 2007; 110(2): 264-70.
15. Bear WL, Teel RW. Effects of citrus flavonoids on the mutagenicity of heterocyclic amines and on cytochrome P450 1A2 activity. Anticancer Res. 2000; 20(5B): 3609-14.
16. Ramelet AA. Clinical benefits of Daflon 500 mg in the most severe stages of chronic venous insufficiency. Angiology. 2001; 52 Suppl 1: S49-56.
17. Labrid C. Pharmacologic properties of Daflon 500 mg. Angiology. 1994; 45(6 Pt 2): 524-30.
18. Bergan JJ, Schmid-Schonbein GW, Takase S. Therapeutic approach to chronic venous insufficiency and its complications: place of Daflon 500 mg. Angiology. 2001; 52 Suppl 1: S43-7.
19. Sroka Z, Fecka I, Cisowski W. Antiradical and anti-H2O2 properties of polyphenolic compounds from an aqueous peppermint extract. Z Naturforsch [C]. 2005; 60(11-12): 826-32.
20. Vicente Ortega V, Martínez Conesa C, Yáñez Gascón J, Alcaraz Baños M, Canteras Jordana M. Melanoma metastásico pulmonar: Efectos del etanol y de flavonoides. R. Española de patología, 2003; 36(4): 425-32.
21. Martínez C, Vicente V, Yáñez J, Alcaraz M, Castells MT, Canteras M, Benavente-García O, Castillo J. The effect of the flavonoid diosmin, grape seed extract and red wine on the pulmonary metastatic B16F10 melanoma. Histol Histopathol. 2005; 20(4): 1121-9.
22. Martínez Conesa C, Vicente Ortega V, Yáñez Gascón MJ, Alcaraz Baños M, Canteras Jordana M, Benavente-García O, Castillo J. Treatment of metastatic melanoma B16F10 by the flavonoids tangeretin, rutin, and diosmin. J Agric Food Chem. 2005a; 53(17): 6791-7.
23. Yang M, Tanaka T, Hirose Y, Deguchi T, Mori H, Kawada Y. Chemopreventive effects of diosmin and hesperidin on N-butyl-N-(4-hydroxybutyl) nitrosamine-induced urinary-bladder carcinogenesis in male ICR mice. Int J Cancer. 1997; 73(5): 719-24.
24. Tanaka T, Kohno H, Mori H. Chemoprevention of Colon Carcinogenesis by Dietary Non-nutritive Compounds. Asian Pac J Cancer Prev. 2001; 2(3): 165-177.
25. Browning AM, Walle UK, Walle T. Flavonoid glycosides inhibit oral cancer cell proliferation--role of cellular uptake and hydrolysis to the aglycones. J Pharm Pharmacol. 2005; 57(8): 1037-42.
26. Martínez Conesa C, Vicente Ortega V, Yáñez Gascón MJ, García Reverte JM, Canteras Jordana M, Alcaraz Baños, M. Experimental model for treating pulmonary metastatic melanoma using grape-seed extract, red wine and etanol. Clin Transl Oncol. 2005b; 7(3): 115-21.
27. Allen PJ, Coit DG. The surgical management of metastatic melanoma. Ann Surg Oncol. 2002; 9(8):762-70.
28. Martínez C, Vicente V, Yañez J, Garcia J, Canteras M, Alcaraz M. Experimental model of pulmonary metastasis treatment with IFNα. Cancer Lett. 2005c; 225(1): 75-83.
29. Wu WJ, Pruett SB. Ethanol decreases host resistance to pulmonary metastases in a mouse model: role of natural killer cells and the ethanol-induced stress response. Int J Cancer. 1999; 82(6): 886-92.
30. Blank SE, Meadows GG. Ethanol modulates metastatic potential of B16BL6 melanoma and host responses. Alcohol Clin Exp Res. 1996; 20(4): 624-8.
31. Wen Y, Yan DH, Wang B, Spohn B, Ding Y, Shao R, Zou Y, Xie K, Hung MC. p202, an interferon-inducible protein, mediates multiple antitumor activities in human pancreatic cancer xenograft models. Cancer Res. 2001; 61(19): 7142-7.
32. Slaton JW, Karashima T, Perrotte P, Inoue K, Kim SJ, Izawa J, Kedar D, McConkey DJ, Millikan R, Sweeney P, Yoshikawa C, Shuin T, Dinney CP. Treatment with low-dose interferon-alpha restores the balance between matrix metalloproteinase-9 and E-cadherin expression in human transitional cell carcinoma of the bladder. Clin Cancer Res. 2001; 7(9): 2840-53.
33. Ozawa S, Shinohara H, Kanayama HO, Bruns CJ, Bucana CD, Ellis LM, Davis DW, Fidler IJ. Suppression of angiogenesis and therapy of human colon cancer liver metastasis by systemic administration of interferon-alpha. Neoplasia. 2001; 3(2): 154-64.
34. Shyu RY, Su HL, Yu JC, Jiang SY. Direct growth suppressive activity of interferon-alpha and -gamma on human gastric cancer cells. J Surg Oncol. 2000; 75(2): 122-30.
35. Yano H, Yanai Y, Momosaki S, Ogasawara S, Akiba J, Kojiro S, Moriya F, Fukahori S, Kurimoto M, Kojiro M. Growth inhibitory effects of interferon-alpha subtypes vary according to human liver cancer cell lines. J Gastroenterol Hepatol. 2006; 21(11): 1720-5.
36. Gutman H, Schachter J, Stopel E, Gutman R, Lahav J. Impaired platelet aggregation in melanoma patients treated with interferon-alpha-2b adjuvant therapy. Cancer. 2002; 94(3): 780-5.
37. Palumbo JS, Talmage KE, Massari JV, La Jeunesse CM, Flick MJ, Kombrinck KW, Jirouskova M, Degen JL. Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells. Blood. 2005; 105(1): 178-85.
38. Im JH, Fu W, Wang H, Bhatia SK, Hammer DA, Kowalska MA, Muschel RJ. Coagulation facilitates tumor cell spreading in the pulmonary vasculature during early metastatic colony formation. Cancer Res. 2004; 64(23): 8613-9.
39. Solis M, Goubau D, Romieu-Mourez R, Genin P, Civas A, Hiscott J. Distinct functions of IRF-3 and IRF-7 in IFN-alpha gene regulation and control of anti-tumor activity in primary macrophages. Biochem Pharmacol. 2006; 72(11): 1469-76.
40. Belardelli F, Ferrantini M, Proietti E, Kirkwood JM. Interferon-alpha in tumor immunity and immunotherapy. Cytokine Growth Factor Rev. 2002; 13(2): 119-34.
41. Hakansson A, Gustafsson B, Krysander L, Hakansson L. Effect of IFN-alpha on tumor-infiltrating mononuclear cells and regressive changes in metastatic malignant melanoma. J Interferon Cytokine Res. 1998; 18(1): 33-9.
42. Le Devehat C, Khodabandehlou T, Vimeux M, Kempf C. Evaluation of haemorheological and microcirculatory disturbances in chronic venous insufficiency: activity of Daflon 500 mg. Int J Microcirc Clin Exp. 1997; 17 Suppl 1: 27-33.
43. Smith PC. Daflon 500 mg and venous leg ulcer: new results from a meta-analysis. Angiology. 2005; 56 Suppl 1: S33-9.
44. Bostrom PJ, Uotila P, Rajala P, Nurmi M, Huhtaniemi I, Laato M. Interferon-alpha inhibits cyclooxygenase-1 and stimulates cyclooxygenase-2 expression in bladder cancer cells in vitro. Urol Res. 2001; 29(1): 20-4.
45. Blank VC, Poli C, Marder M, Roguin LP. Antiproliferative activity of various flavonoids and related compounds: additive effect of interferon-alpha2b. Bioorg Med Chem Lett. 2004; 14(1): 133-6.
46. Sundelin K, Roberg K, Grenman R, Hakansson L. Effects of cisplatin, alpha-interferon, and 13-cis retinoic acid on the expression of Fas (CD95), intercellular adhesion molecule-1 (ICAM-1), and epidermal growth factor receptor (EGFR) in oral cancer cell lines. J Oral Pathol Med. 2007; 36(3): 177-83.
47. Hussein MR. Dendritic cells and melanoma tumorigenesis: an insight. Cancer Biol Ther. 2005; 4(5): 501-5.
48. Matsuda H, Morikawa T, Ando S, Toguchida I, Yoshikawa M. Structural requirements of flavonoids for nitric oxide production inhibitory activity and mechanism of action. Bioorg Med Chem. 2003; 11(9): 1995-2000.
49. Menegazzi M, Tedeschi E, Dussin D, De Prati AC, Cavalieri E, Mariotto S, Suzuki H. Anti-interferon gamma action of epigallocatechin-3-gallate mediated by specific inhibition of STAT1 activation. FASEB J. 2001; 15(7): 1309-11.
50. Matsuda T, Ferreri K, Todorov I, Kuroda Y, Smith CV, Kandeel F, Mullen Y. Silymarin protects pancreatic beta-cells against cytokine-mediated toxicity: implication of c-Jun NH2-terminal kinase and janus kinase/signal transducer and activator of transcription pathways. Endocrinology. 2005; 146(1): 175-85.